Treatment of focal segmental glomerulosclerosis

Patrizia Passerini, Claudio Ponticelli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to endstage renal disease in approximately 50-70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalCurrent Opinion in Nephrology and Hypertension
Volume10
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Focal Segmental Glomerulosclerosis
Steroids
Pefloxacin
Mycophenolic Acid
Blood Component Removal
Plasmapheresis
Cytotoxins
Azathioprine
Tacrolimus
Therapeutics
Vitamin E
Cyclosporine
Clinical Trials
Kidney

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Treatment of focal segmental glomerulosclerosis. / Passerini, Patrizia; Ponticelli, Claudio.

In: Current Opinion in Nephrology and Hypertension, Vol. 10, No. 2, 2001, p. 189-193.

Research output: Contribution to journalArticle

Passerini, Patrizia ; Ponticelli, Claudio. / Treatment of focal segmental glomerulosclerosis. In: Current Opinion in Nephrology and Hypertension. 2001 ; Vol. 10, No. 2. pp. 189-193.
@article{376eac4d94714b348aed1c49351ef073,
title = "Treatment of focal segmental glomerulosclerosis",
abstract = "The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to endstage renal disease in approximately 50-70{\%} of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.",
author = "Patrizia Passerini and Claudio Ponticelli",
year = "2001",
doi = "10.1097/00041552-200103000-00006",
language = "English",
volume = "10",
pages = "189--193",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment of focal segmental glomerulosclerosis

AU - Passerini, Patrizia

AU - Ponticelli, Claudio

PY - 2001

Y1 - 2001

N2 - The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to endstage renal disease in approximately 50-70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.

AB - The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to endstage renal disease in approximately 50-70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.

UR - http://www.scopus.com/inward/record.url?scp=0035100843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035100843&partnerID=8YFLogxK

U2 - 10.1097/00041552-200103000-00006

DO - 10.1097/00041552-200103000-00006

M3 - Article

C2 - 11224693

AN - SCOPUS:0035100843

VL - 10

SP - 189

EP - 193

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 2

ER -